Investigating Monocytes in Patients with Atrophic Age-Related Macular Degeneration
Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants
This study is testing how certain immune cells in people with atrophic age-related macular degeneration might affect the disease and looking for clues that could lead to new treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 15 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Lyon and 1 other locations) |
| Trial ID | NCT04697095 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with atrophic age-related macular degeneration (AMD), a leading cause of irreversible blindness. It aims to analyze monocytes collected from these patients to understand their survival and the role of cytokines in the disease process. By examining the inflammatory response in the sub-retinal space, the study seeks to identify specific cytokines that may contribute to the progression of AMD. The findings could pave the way for potential therapeutic strategies for atrophic AMD, which currently lacks effective treatment.
Who should consider this trial
Good fit: Ideal candidates include individuals over 50 years old with either atrophic or early forms of AMD.
Not a fit: Patients with a weight less than 50kg or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic approaches for treating atrophic AMD, potentially improving patient outcomes.
How similar studies have performed: While there is ongoing research into the role of inflammatory cells in AMD, this specific approach focusing on monocytes in atrophic AMD is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: General criteria: * Male or female older than 50, * Provide written informed consent, * Patient affiliated to French social security, * Maximum sampling volume (care + research) per 30-day period to be adapted according to the weight of the patient Specific criteria: Patient presenting in both eyes: * Either the same type of AMD defined according to the modified international AREDS study (Ferris et al. 2013), * or early AMD in one eye and atrophic AMD in the other eye, the patient will therefore be defined as being atrophic * or early AMD in one eye and exudative AMD in the other eye, the patient will therefore be defined as exudative, * or no retinal pathology (control group). Exclusion Criteria: General criteria: * Patient whose weight is less than 50kg, * Adult patient under guardianship or curatorship or unable to express consent, * Person deprived of liberty, * Patient participating in an ongoing clinical trial during the inclusion visit, Specific criteria: * Patient with atrophic AMD in one eye and exudative AMD in the other eye, * Patient presenting with chronic retinal pathologies other than AMD, defined according to the modified international AREDS study (Ferris et al. 2013) , in the included eye, * Patient taking systemic drugs with an immunomodulatory action: immunosuppressants, immunomodulators, chemotherapy or corticosteroids, * Patient with systemic pathologies modifying their immune status, * Patient with a history of diabetes, * Patient who had dynamic phototherapy on the included eye.
Where this trial is running
Lyon and 1 other locations
- Hôpital Edouard Herriot — Lyon, France (Recruiting)
- Service d'ophtalmologie-HOSPICES CIVILS DE LYON - Hôpital de la Croix-Rousse — Lyon, France (Recruiting)
Study contacts
- Principal investigator: Thibaud Mathis, MD — Service d'Ophtalmologie Hospices Civils de Lyon Hôpital de la Croix Rousse
- Study coordinator: Thibaud Mathis, MD
- Email: thibaud.mathis@chu-lyon.fr
- Phone: 4 26 10 93 22
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.